3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Completed
15
Terminated
7
Active not recruiting
3
Recruiting
2
Withdrawn
1
Unknown
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Tumor-Agnostic
2
Conditions
Neoplasms
2
Interventions
pembrolizumab
223
Carboplatin
222
Specimen Handling
194
Cisplatin
192
Magnetic Resonance Spectroscopy
165
Radiotherapy
153
Bevacizumab
143
Gemcitabine
136
Cyclophosphamide
135
Drug Therapy
119
Capecitabine
118
Paclitaxel
116
Oxaliplatin
111
Nivolumab
105
Biopsy
104
venetoclax
103
tislelizumab
83
Rituximab
83
durvalumab
82
toripalimab
78
Fluorouracil
73
Etoposide
72
Docetaxel
69
Dexamethasone
69
sintilimab
67
Pemetrexed
67
atezolizumab
65
Radiosurgery
65
Azacitidine
63
130-nm albumin-bound paclitaxel
62
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2
×
Recruiting
×
rucaparib
×
Clear all
NCT03899155
2026-05-27
Pan Tumor Rollover Study
Bristol-Myers Squibb
Phase 2
Recruiting
1,500 enrolled
NCT02925234
2024-01-24
DRUP
The Netherlands Cancer Institute
Phase 2
Recruiting
1,550 enrolled